Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.

ABSTRACT: Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or more after diagnosis. Despite aggressive multimodal therapy, consisting mostly of a combination of surgery, radiotherapy, and temozolomide chemotherapy, tumors nearly always recur close to the site of resection. For the past 15 years, very little progress has been made with regards to improving patient survival. Although immunotherapy represents an attractive therapy modality due to the promising pre-clinical results observed, many of these potential immunotherapeutic approaches fail during clinical trials, and to date no immunotherapeutic treatments for GBM have been approved. As for many other difficult to t

SUBMITTER: Pearson JRD 

PROVIDER: S-EPMC7594513 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature